We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Reasons Why Danaher (DHR) Should be in Your Portfolio Now
Read MoreHide Full Article
Danaher Corporation (DHR - Free Report) is well poised for growth courtesy of strength across its end markets, strategic acquisitions and its focus on improving the product line and operational excellence.
Image Source: Zacks Investment Research
The company has a market capitalization of $180.7 billion. In the past six months, the stock has gained 16.5% compared with the industry’s growth of 5.4%. DHR currently carries a Zacks Rank #2 (Buy).
Let’s delve into the factors that have been aiding the firm for a while now.
Business Strength: Danaher has been benefiting from strength in the Life Sciences segment, driven by strong demand in the academic and life science research markets. Growth in demand for plasmids, proteins, gene writing and editing solutions augurs well for the segment.
The company has been witnessing positive responses from new products like IDBS' Polar Insight and Molecular Devices' CellXpress.ai, which help accelerate the drug discovery process and bring new therapies to market faster. Also, the Diagnostics unit has been gaining from growing popularity for new solutions like Beckman Coulter's DxI 9000 next-generation immunoassay analyzer in the market.
Acquisition Benefits: DHR is focused on acquiring businesses to gain access to new customers, regions and product lines. In December 2023, Danaher acquired Abcam plc, a global supplier of protein consumables, for $5.7 billion. The inclusion of Abcam's strong innovation capabilities and robust product line are expected to help Danaher solve some of the greatest healthcare challenges. This buyout expanded the company’s Life Sciences segment. These acquisitions boosted the company’s total revenues by 0.5% in 2023.
DBS Initiatives: The Danaher Business System (DBS) initiatives, which help Danaher focus more on product innovation, superior product quality, efficient workforce building and shareholder value enhancement, are fostering the company’s growth. As part of the DBS initiatives, disciplined cost management, enhanced productivity and pricing actions have supported the company’s performance.
Shareholder-Friendly Policies: DHR is committed to rewarding its shareholders through dividend payouts. In 2023, the company paid out dividends of $821 million, up 0.4% year over year. In February 2024, the quarterly dividend rate was hiked by 12.5% to 27 cents per share.
Other Stocks to Consider
Some other top-ranked companies from the same space are discussed below.
The company has a trailing four-quarter average earnings surprise of 10.2%. The Zacks Consensus Estimate for VGR’s 2024 earnings has decreased 6.9% in the past 60 days.
Carlisle Companies Incorporated (CSL - Free Report) currently carries a Zacks Rank #2. CSL delivered a trailing four-quarter average earnings surprise of 7.6%. In the past 60 days, the Zacks Consensus Estimate for CSL’s 2024 earnings has increased 3.8%.
Cadre Holdings, Inc. (CDRE - Free Report) presently has a Zacks Rank of 2. CDRE delivered a trailing four-quarter average earnings surprise of 45.6%. In the past 60 days, the Zacks Consensus Estimate for Cadre’s 2024 earnings has increased 7.3%.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Shutterstock
Reasons Why Danaher (DHR) Should be in Your Portfolio Now
Danaher Corporation (DHR - Free Report) is well poised for growth courtesy of strength across its end markets, strategic acquisitions and its focus on improving the product line and operational excellence.
Image Source: Zacks Investment Research
The company has a market capitalization of $180.7 billion. In the past six months, the stock has gained 16.5% compared with the industry’s growth of 5.4%. DHR currently carries a Zacks Rank #2 (Buy).
Let’s delve into the factors that have been aiding the firm for a while now.
Business Strength: Danaher has been benefiting from strength in the Life Sciences segment, driven by strong demand in the academic and life science research markets. Growth in demand for plasmids, proteins, gene writing and editing solutions augurs well for the segment.
The company has been witnessing positive responses from new products like IDBS' Polar Insight and Molecular Devices' CellXpress.ai, which help accelerate the drug discovery process and bring new therapies to market faster. Also, the Diagnostics unit has been gaining from growing popularity for new solutions like Beckman Coulter's DxI 9000 next-generation immunoassay analyzer in the market.
Acquisition Benefits: DHR is focused on acquiring businesses to gain access to new customers, regions and product lines. In December 2023, Danaher acquired Abcam plc, a global supplier of protein consumables, for $5.7 billion. The inclusion of Abcam's strong innovation capabilities and robust product line are expected to help Danaher solve some of the greatest healthcare challenges. This buyout expanded the company’s Life Sciences segment. These acquisitions boosted the company’s total revenues by 0.5% in 2023.
DBS Initiatives: The Danaher Business System (DBS) initiatives, which help Danaher focus more on product innovation, superior product quality, efficient workforce building and shareholder value enhancement, are fostering the company’s growth. As part of the DBS initiatives, disciplined cost management, enhanced productivity and pricing actions have supported the company’s performance.
Shareholder-Friendly Policies: DHR is committed to rewarding its shareholders through dividend payouts. In 2023, the company paid out dividends of $821 million, up 0.4% year over year. In February 2024, the quarterly dividend rate was hiked by 12.5% to 27 cents per share.
Other Stocks to Consider
Some other top-ranked companies from the same space are discussed below.
Vector Group Ltd. (VGR - Free Report) presently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
The company has a trailing four-quarter average earnings surprise of 10.2%. The Zacks Consensus Estimate for VGR’s 2024 earnings has decreased 6.9% in the past 60 days.
Carlisle Companies Incorporated (CSL - Free Report) currently carries a Zacks Rank #2. CSL delivered a trailing four-quarter average earnings surprise of 7.6%. In the past 60 days, the Zacks Consensus Estimate for CSL’s 2024 earnings has increased 3.8%.
Cadre Holdings, Inc. (CDRE - Free Report) presently has a Zacks Rank of 2. CDRE delivered a trailing four-quarter average earnings surprise of 45.6%. In the past 60 days, the Zacks Consensus Estimate for Cadre’s 2024 earnings has increased 7.3%.